Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho
Nadine Tschumi, Malebanye Lerotholi, Lipontso Motaboli, Moliehi Mokete, Niklaus Daniel Labhardt, Jennifer Anne Brown
Abstract
In the Viral Load Cohort North-East Lesotho (VICONEL) human immunodeficiency virus cohort, 14 242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021. Rates of viral suppression to <50 copies/mL were 84.8%, 93.9%, and 95.4% before, 12 months after, and 24 months after transition, respectively. Sex, age, pretransition viral load, and treatment backbone correlated with 24-month viremia.
Topics & Concepts
DolutegravirMedicineEfavirenzCohortViremiaNevirapineHuman immunodeficiency virus (HIV)Viral loadVirologyAntiretroviral therapyPediatricsInternal medicineHIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment